Samsara BioCapital related stories
All articles and analysis
VC-backed Sutro Biopharma debuts IPOSouth San Francisco-based Sutro Biopharma Inc, a drug developer focused on creating protein therapeutics for cancer and autoimmune disorders, has raised about $85 million after pricing its over 5.6 million shares at $15 per share. The stock began trading September 27, 2018 on the NASDAQ under the ticker symbol "SRO." Cowen and Piper Jaffray are the lead underwriters. Also, Sutro has raised about $10 million in a private placement from Merck. Sutro's pre-IPO investors included Samsara BioCapital, Surveyor Capital, Alta Partners, Amgen Ventures, Celgene Corporation, Lilly Ventures, Skyline Ventures and SV Health Investors.
- Biotech firm Atreca rakes in $125 mln Series C
Redwood City, California-based Atreca Inc, a biotechnology company, has secured $125 million in Series C financing. The investors included Wellington Management Company LLC, Cormorant Asset Management, Aisling Capital, Boxer Capital of the Tavistock Group, EcoR1 Capital, Redmile Group, Samsara BioCapital and funds managed by Tekla Capital Management.
- Sutro Biopharma snags $85.4 mln Series E
South San Francisco-based Sutro Biopharma Inc, a drug developer, has secured $85.4 million in Series E financing. Samsara BioCapital and Surveyor Capital led the round with participation from other investors that included Alta Partners, Amgen Ventures, Celgene Corporation, Lilly Ventures, Skyline Ventures and SV Health Investors. In addition to the funding, Dr. Mike Dybbs, a partner at Samsara BioCapital, will join the Sutro board of directors.
- Samsara BioCapital raises $310 mln for venture-capital fund
Samsara BioCapital has raised $310 million for a venture-capital fund, according to a filing with the SEC.
- Samsara BioCapital raises $260.6 mln for venture capital fund
Samsara BioCapital has raised $260.6 million toward a $300 million venture-capital fund, according to a filing with the SEC.
- Samsara BioCapital to raise $300 mln venture fund
Samsara BioCapital has set out to raise a $300 million venture fund, according to a filing with the SEC.